Verhoef LM, den Broeder N, Thurlings, et al. Ultra-low doses of rituximab or retreatment of rheumatoid arthritis: a randomised controlled non-inferiority trial. EULAR 2019; Madrid: Abstract LB0010.
Anti-C5a-antilichaam vilobelimab veilig bij ernstige COVID-19
feb 2021 | Pneumonie, Virale infecties